

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
12 February 2004 (12.02.2004)

PCT

(10) International Publication Number  
**WO 2004/012706 A1**

(51) International Patent Classification<sup>7</sup>: **A61K 9/08**,  
31/19, 31/198, 31/401, 31/405, 31/4172, A61M 1/28

MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC,  
SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA,  
UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(21) International Application Number:  
PCT/EP2003/008226

(22) International Filing Date: 25 July 2003 (25.07.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
TO2002 A 000672 26 July 2002 (26.07.2002) IT

(71) Applicant (for all designated States except US):  
**MEDESTEA RESEARCH & PRODUCTION S.R.L.**  
[IT/IT]; Via Ribes 5, I-10010 Colletterto Giacosa (IT).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **FRANZONE, Josè**,  
Sebastian [IT/IT]; Via Maria Vittoria 23, I-10123 Torino  
(IT). **OMINI, Claudio** [IT/IT]; Piazza Cavour, 5, I-20060  
Bussero (IT). **ZUCCARI, Giuseppe** [IT/IT]; Via Europa,  
25, I-26866 Sant'Angelo Lodigiano (IT).

(74) Agents: **RAMBELLI, Paolo** et al.; Jacobacci & Partners  
S.p.A., Corso Regio Parco, 27, I-10152 Torino (IT).

(81) Designated States (national): AE, AG, AL, AM, AT, AU,  
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,  
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,  
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,  
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,

(84) Designated States (regional): ARIPO patent (GH, GM,  
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),  
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),  
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,  
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO,  
SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM,  
GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

**Declarations under Rule 4.17:**

- as to applicant's entitlement to apply for and be granted  
a patent (Rule 4.17(ii)) for the following designations AE,  
AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA,  
CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES,  
FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,  
KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD,  
MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH,  
PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN,  
TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, ARIPO  
patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG,  
ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU,  
TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE,  
DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT,  
RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM,  
GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)
- of inventorship (Rule 4.17(iv)) for US only

**Published:**

- with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: PHARMACEUTICAL COMPOSITIONS CONTAINING KETO-ACIDS FOR ENDOPERITONEAL ADMINISTRATION

(57) Abstract: Pharmaceutical compositions are described containing ketoaminoacids such as keto-isoleucine, keto-leucine, keto-phenyl alanine, keto-valine and keto-hydroxy-methionine, optionally in association with essential aminoacids and/or vitamins and their use for intraperitoneal administration as a dietary supplement for subjects affected by renal failure or weakness.

WO 2004/012706 A1

Pharmaceutical compositions containing keto-acids for endo-peritoneal administration

The present invention relates to a new use pharmaceutical and in particular to a new way of administration of keto-acids useful as dietary supplements for patients with renal failure.

The emunctory apparatus, of which the kidneys represent an essential element, plays a determining role in the physiological functionality contributing significantly to the maintenance of correct homeostasis of the organism. The kidneys have the function of cleansing from the blood the majority of the products of cellular catabolism and, in particular, the products of catabolism of proteins, which constitutes the majority of the nitrogenous compounds. Renal failure, induced by whatever etiological cause, is characterised by a greater or lesser reduction in the capacity of the kidneys adequately to filter the circulating blood and is characterised by an increase in azotemia. Renal failure can be classified as acute or chronic type. A sharp and often reversible partial or total interruption of the filtration capacity of the kidney, characterised by a substantial reduction in the urinary volume, is classified as acute renal failure (ARF). From the clinical point of view, ARF is associated with a rapid and constant increase of azotemia with the presence or absence of oliguria (<500ml/per day). The second condition of renal failure is the so-called chronic renal failure (CRF) with various etiopathologies and progressive reduction of the filtering capacity of the kidneys. In CRF a progressive distribution of the nephrones is normally observed, which progressively reduces the renal functionality. Cachetia, with loss of both muscular and fat mass, retardation in the growth of

children, and diminished protein synthesis are easily observable in those suffering from CRF. Therefore these patients necessitate, in the case of chronic illness, a meticulous attention to the dietetic treatment, as the chronic renal failure gradually develops (1). The correct dietetic dose must be instigated for the purpose of counteracting anorexia, which is one of the early symptoms of this illness. In this context, however, the dose of dietetic protein must be suitably reduced and it has therefore become firmly established that when used in patients with chronic renal failure and in particular those subjected to dialysis, such patients receive an adequate supplement with essential aminoacids. This clinical practice is extremely widespread and numerous scientific studies have attested the validity thereof.

In particular, the use of keto-acids such as keto-isoleucine, keto-leucine, keto-phenyl alanine, keto-valine, etc., which are precursors of essential aminoacids and are directly transformed into corresponding natural aminoacids by the organism after ingestion, have the advantage of reducing the degree of plasmatic urea, of reducing the synthesis of urea and its excretion, and significantly improving the nitrogen balance (2). The aminoacids are traditionally administered to the patient undergoing haemodialysis by venous means with suitable formulations. However, more recently numerous clinical studies (3, 4, 5) have indicated that the oral administration of aminoacids and keto-acids is efficacious as a dietary supplement for patients with renal failure.

Currently there are several commercially available preparations based on keto-acids for use in the oral administration of patients with chronic renal failure. However, these formulations are those traditionally used and in particular take

the form of tablets and must be taken even with a posology of ten tablets three times per day. The low practicality and intrinsic difficulty of taking such formulations is entirely evident. The object of the present invention is that of obtaining formulations for intraperitoneal administration and endovenous administration containing keto-acids possibly associated with aminoacids and vitamins as a dietetic supplement for the patient with renal failure or, in general, weakened patients, which are pharmaceutically acceptable and which improve the patient's compliance. It is known in the art that keto-acids administered orally are transformed in the body into corresponding aminoacids by means of a process of transamination effected in part at the cost of non essential aminoacids obtained from the diet and in part with the use of ammonium in the form of ammonia produced by intestinal bacteria.

It is likewise known that the endovenous administration of keto-acids in subjects affected by a deficit of carbamyl phosphate synthetase (6) have shown a rapid increase in the concentration of the respective aminoacids in the serum. The intraperitoneal administration of keto-acids is not known.

Within the scope of the present invention it has been observed, in tests performed on rabbits, that the intraperitoneal administration of a mixture of keto-acids has also caused the appearance, at the serum level, of corresponding aminoacids. Therefore, in correspondence with what is observed for oral administration, the intraperitoneal administration of a mixture of keto-acids has caused a significant increase in the serum of leucine and isoleucine ( $p < 0.02$ ), and valine ( $p < 0.05$ ). It is interesting to observe how the endovenous administration of keto-acids causes a rapid plas-

matic peak of corresponding aminoacids, but that this becomes exhausted equally rapidly because of the rapid incorporation of these into the protein structures. As opposed to endovenous administration and very much more advantageously, the intraperitoneal administration of keto-acids causes a plasmatic concentration of the corresponding aminoacids more slowly to start with but over a more extended time. This action is evidently an advantage with respect to the endovenous method of administration. In fact, the intraperitoneal administration of the keto-acids makes possible a more protracted temporal use of the compounds in a manner similar to that of oral administration, which has been shown to have been effective in dialysed subjects, whilst preventing the already described disadvantages of the necessity for taking up to ten tablets several times a day. It is in fact an entirely surprising result that the single intraperitoneal administration of a solution of keto-acids, such as that hereinafter reported, has made it possible to obtain a sufficient daily quantity of aminoacid supplementation in dialysed patients. It is moreover important to underline how the use of keto-acids in association with essential aminoacids leads to a consistent improvement in efficacy and therefore in the present invention there are likewise preferred the formulations suited to intraperitoneal administration comprising the association of keto-acid and aminoacids.

The subject of the invention is defined by the claims which follow.

For the single purpose of better representing the present invention the following examples of inventive formulations, with an indication of the usable dosage interval, are provided hereinafter.

Example 1

100 g of formulation containing:

keto-isoleucine 0.1-1.9 g;

keto-leucine 0.1-2.2 g;

keto-valine 0.30-2.10 g;

keto-hydroxy-methionine 0.1-1.5 g;

L-phenyl-alanine 0.10-1.90 g;

L-lysine 0.5-2.5 g;

L-threonine 0.2-2.0 g;

L-histidine 0.1-1.0 g;

L-tyrosine 0.01-0.2 g;

HCl 37% q.s. (as needed) to pH 7.0+/- 0.2;

Na metabisulphite 0.05 g;

water for injectable preparations q.s. (as needed) to 100 g.

Example 2

1000 ml of formulation containing:

Ca keto-isoleucine 0.3-2.9 g

Ca keto-leucine 0.1-3.2 g

Ca keto-valine 0.5-4.1 g

Ca keto-hydroxy-methionine 0.1-1.15 g

L-phenyl-alanine 0.1-1.5 g

L-lysine 0.5-2.5 g

L-threonine 0.2-2.0 g

L-histidine 0.1-1.5 g

L-tyrosine 0.01-1.0 g

L-serine 0.05-1.5 g

L-tryptophan 0.05-1.0 g

L-alanine 0.05-2.5 g

L-arginine 0.3-2.5 g

Glycine 0.03-1.5 g  
L-proline 0.1-1.5 g  
Na lactate 2.0-8.0 g  
NaCl 2.0-10 g  
MgCl<sub>2</sub> 0.01-1 g  
HCl q.s. to pH 6.5-7.0  
H<sub>2</sub>O q.s. to 1000 ml

These formulations are easily obtainable by one skilled in the art, possibly referring to texts in use in the pharmaceutical field. These formulations are liquid and stable over time; moreover, since the formulations are easily dispersible cold in water or other aqueous liquids suitable for endovenous or intraperitoneal administration in man, such as for example a physiological solution, glucosate solution etc, the injectable formulation can easily be prepared even extemporaneously and immediately before use. In the above cited example sodium metabisulphite was utilised as preservative agent, however other substances normally used for the preservation of injectable pharmaceutical products can likewise be utilised.

The association of vitamins, in particular of group B, is likewise within the scope of the present invention in that the necessity to supplement the dialysed subject with poly-vitamin preparations is known in the art. Therefore the use of formulations such as that indicated above in association with water-soluble poly-vitamin complexes is entirely straightforward and represents an undeniable advantage of the present invention. Moreover, if required, salts of usable keto-acids can be based on Ca or other cations or possibly the formulation can be added to specific water-soluble salts to comply with the patient's requirements.

Solely for the purpose of better further representing the formulations described hereinabove in the present invention the following specific example is provided.

Example 3

100 g of formulation containing:

salts of calcium of: keto-isoleucine 0.5 g, keto-leucine 1.0 g;  
keto-valine 0.8 g;  
keto-hydroxy-methionine 0.4 g;  
L-phenyl alanine 0.40 g;  
L-lysine 1.0 g;  
L-threonine 1.0 g;  
L-histidine 0.4 g;  
L-tyrosine 0.03 g;  
vitamin B1 0.01 g;  
vitamin B2 0.005 g;  
vitamin B6 0.004 g;  
nicotinamide 0.04 g;  
D-panthothenol 0.006 g;  
vitamin B12 8 mcg;  
biotin 500 mcg;  
HCL 37% as necessary pH 7.0 +/- 0.2;  
Na metabisulphite 0.05 g;  
water for injectable preparations as necessary to 100 g.

Bibliography:

1. Merck manual of diagnosis and therapy 2<sup>nd</sup> Italian edition 1990
2. Fynn ES et al; Am. J. Clin. Nutr. 1978; 31(10) : 1776-83
3. Ulm A. et al; Am. J. Clin. Nutr. 1978; 31(10) : 1827-30
4. Hecking E. et al; Z Ernahrungswiss 1982; 21(4) : 299-311



5. Dalton RN & Chantler C.; Kidney Int. Suppl. 1983; 15:  
S11-5
6. Batshaw M et al; N. Eng. J. Med. 1975; 292: 1085-90

CLAIMS

1. Pharmaceutical compositions for intraperitoneal administration containing keto-acids and their pharmaceutically acceptable salts as a dietary supplement for patients with renal failure or weakness.

2. Compositions according to claim 1 containing keto-acids selected from the group consisting of keto-isoleucine, keto-leucine, keto-phenyl alanine, keto-valine, keto-hydroxy-methionine and mixtures thereof.

3. Compositions according to claim 1 or claim 2 containing a keto-acid selected from the following group, in the quantities indicated:

keto-isoleucine 0.1-1.9 g;

keto-leucine 0.1-2.2 g;

keto-valine 0.30-2.10 g;

keto-hydroxy-methionine 0.1-1.5 g;

and their mixtures for 100 g of final formulation.

4. Compositions according to any preceding claims, containing keto-acids in association with aminoacids.

5. Compositions according to claim 4, containing an amino-acid selected from the following group, in the quantities indicated:

L-phenyl-alanine 0.10-1.90 g;

L-lysine 0.5-2.5 g;

L-threonine 0.2-2.0 g;

L-histidine 0.1-1.0 g;

L-tyrosine 0.01-0.2 g;

and their mixtures to 100 g of final formulation.

6. Compositions according to claim 4, containing aminoacids selected from the following group, in the quantities indicated:

L-phenyl-alanine 0.1-1.5 g

L-lysine 0.5-2.5 g

L-threonine 0.2-2.0 g

L-histidine 0.1-1.5 g

L-tyrosine 0.01-1.0 g

L-serine 0.05-1.5 g

L-tryptophan 0.05-1.0 g

L-alanine 0.05-2.5 g

L-arginine 0.3-2.5 g

Glycine 0.03-1.5 g

L-proline 0.1-1.5 g

and their mixtures to 1000 ml of final formulation.

7. Compositions according to claim 6 containing the following compounds, in the quantities indicated:

Na lactate 2.0-8.0 g

NaCl 2.0-10 g

MgCl<sub>2</sub> 0.01-1 g

HCl q.s. to pH 6.5-7.0

H<sub>2</sub>O q.s. 1000 ml

8. Compositions according to any of claims 1 to 7 containing keto-acids, aminoacids and vitamins.

9. Compositions according to claim 8 containing water-soluble vitamins of group B.

10. Compositions according to claim 9, containing vitamins selected from the group which consists of vitamin B1, vitamin

B2, vitamin B6, vitamin B12, nicotinamide, D-panthothenol and mixtures thereof.

11. Compositions according to any of claims 1 to 10, containing salts with cations of said keto-acids, optionally with added inorganic and organic salts.

12. Compositions according to any of claims 1 to 11, dissolved in strictly aqueous solutions suitable for parenteral administration.

13. Compositions according to any of claims 1 to 12 in packaging containing multi-dose, mono-dose, daily mono-dose ready for use or alternatively to be dissolved ready for use.

14. The use of a composition according to any of claims 1 to 13 for the preparation of a pharmaceutical for intraperitoneal administration as a dietary supplement in the treatment of patients with renal failure or weakness.

# INTERNATIONAL SEARCH REPORT

International Application No

PC 17/EP 03/08226

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A61K9/08 A61K31/19 A61K31/198 A61K31/401 A61K31/405  
A61K31/4172 A61M1/28

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K A61M

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, BIOSIS, MEDLINE, CHEM ABS Data

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 86 00227 A (VEECH RICHARD L) 16 January 1986 (1986-01-16) page 64, line 1 -page 67, line 3 table VIII claim 28	1-14
X	US 5 536 751 A (BUNGER ROLF) 16 July 1996 (1996-07-16) examples 5,6	1-14
X	WO 96 01118 A (BAXTER INT) 18 January 1996 (1996-01-18) page 4, line 25 - line 32 page 5, line 14 - line 26 page 7, line 30 -page 8, line 10	1-14
	--- -/--	

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

### \* Special categories of cited documents :

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

- \*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- \*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- \*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- \*Z\* document member of the same patent family

Date of the actual completion of the international search

23 October 2003

Date of mailing of the international search report

29/10/2003

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax (+31-70) 340-3016

Authorized officer

Giménez Miralles, J

# INTERNATIONAL SEARCH REPORT

International Application No  
PCT/EP 03/08226

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EP 0 431 465 A (NEPHRO MEDICA PHARMA) 12 June 1991 (1991-06-12) page 4, line 41 -page 6, line 21 page 7, line 29 - line 32 examples	1-14
X	DE 39 43 424 A (NEPHRO MEDICA PHARMA) 4 July 1991 (1991-07-04)	1-13
Y	page 3, line 2 -page 4, line 23 page 5, line 14 - line 53 examples	14
X	ULM A ET AL: "INFLUENCE OF ESSENTIAL AMINO ACIDS AND KETO ACIDS ON PROTEIN METABOLISM AND ANEMIA OF PATIENTS ON INTERMITTENT HEMODIALYSIS" AMERICAN JOURNAL OF CLINICAL NUTRITION, BETHESDA, MD, US, vol. 31, no. 10, October 1978 (1978-10), pages 1827-1830, XP008010155 ISSN: 0002-9165 cited in the application	1-13
Y	the whole document	14
X	EP 0 405 295 A (ABBOTT LAB) 2 January 1991 (1991-01-02)	1-13
Y	page 4, line 3 -page 5, line 27 examples	14
X	US 4 752 619 A (BORDAT CLAUDE ET AL) 21 June 1988 (1988-06-21)	1-13
Y	column 2, line 42 -column 3, line 17 column 6, line 3 - line 11 examples	14
X	US 4 100 160 A (WALSER MACKENZIE) 11 July 1978 (1978-07-11)	1-13
Y	column 4, line 52 -column 6, line 33 table III	14
A	WO 94 14430 A (BAXTER INT) 7 July 1994 (1994-07-07) page 4, line 22 -page 5, line 29	1-14

## INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 03/08226

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 8600227	A	16-01-1986	AT 82500 T AU 4634685 A AU 4771690 A AU 7746694 A CA 1264442 A1 DE 3586844 D1 DE 3586844 T2 EP 0185759 A1 JP 61502943 T WO 8600227 A1 US 4663289 A US 4663166 A	15-12-1992 24-01-1986 13-09-1990 05-01-1995 16-01-1990 24-12-1992 17-03-1994 02-07-1986 18-12-1986 16-01-1986 05-05-1987 05-05-1987
US 5536751	A	16-07-1996	US 5714515 A	03-02-1998
WO 9601118	A	18-01-1996	AT 222766 T AU 701724 B2 AU 2655195 A BR 9506021 A CA 2169451 A1 CN 1131393 A DE 69527923 D1 DE 69527923 T2 EP 0716607 A1 JP 2001523212 T TR 960008 A2 WO 9601118 A1 US 2002037329 A1	15-09-2002 04-02-1999 25-01-1996 14-10-1997 18-01-1996 18-09-1996 02-10-2002 24-04-2003 19-06-1996 20-11-2001 21-06-1996 18-01-1996 28-03-2002
EP 0431465	A	12-06-1991	DE 3940052 A1 AT 104149 T DE 59005355 D1 DK 431465 T3 WO 9108009 A1 EP 0431465 A1 ES 2054200 T3	06-06-1991 15-04-1994 19-05-1994 08-08-1994 13-06-1991 12-06-1991 01-08-1994
DE 3943424	A	04-07-1991	DE 3943424 A1	04-07-1991
EP 0405295	A	02-01-1991	US 4957938 A AT 91392 T AU 627041 B2 AU 5767390 A CA 2019472 A1 DE 69002201 D1 DE 69002201 T2 EP 0405295 A2 ES 2058687 T3 JP 3031211 A	18-09-1990 15-07-1993 13-08-1992 03-01-1991 21-12-1990 19-08-1993 05-01-1994 02-01-1991 01-11-1994 12-02-1991
US 4752619	A	21-06-1988	AT 67088 T AU 592395 B2 AU 6691786 A CA 1286990 C DE 3681420 D1 DK 622486 A EP 0227545 A2 ES 2025560 T3	15-09-1991 11-01-1990 25-06-1987 30-07-1991 17-10-1991 24-06-1987 01-07-1987 01-04-1992

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 03/08226

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 4752619	A	FI 865268 A , B, GR 3003272 T3 JP 62270522 A KR 9402661 B1 NO 865217 A PT 83995 A , B	24-06-1987 17-02-1993 24-11-1987 28-03-1994 24-06-1987 01-01-1987
US 4100160	A 11-07-1978	BE 827890 A1 CA 1057198 A1 DE 2516027 A1 FR 2274290 A2 GB 1511302 A NL 7504408 A	31-07-1975 26-06-1979 16-10-1975 09-01-1976 17-05-1978 17-10-1975
WO 9414430	A 07-07-1994	AT 226433 T AU 678201 B2 AU 5748894 A CA 2129998 A1 DE 69332433 D1 DE 69332433 T2 DK 626845 T3 EP 0626845 A1 ES 2185646 T3 JP 7504210 T MX 9308002 A1 NZ 259242 A SG 48704 A1 WO 9414430 A1 US 5670176 A US 5698230 A US 5776503 A	15-11-2002 22-05-1997 19-07-1994 07-07-1994 28-11-2002 14-08-2003 17-02-2003 07-12-1994 01-05-2003 11-05-1995 31-08-1994 24-03-1997 18-05-1998 07-07-1994 23-09-1997 16-12-1997 07-07-1998